News
Announcements and milestones.
Curatio sharpens its focus on CNS oncology
Curatio Therapeutics is concentrating its resources on cancers of the brain and central nervous system. LMP01, the company’s combination therapy with intranasal delivery, remains its lead program in IDH wild-type glioblastoma, with planned expansion into recurrent high-grade gliomas, brain metastases, leptomeningeal disease, primary CNS lymphoma and pediatric high-grade gliomas.
FDA grants Orphan Drug Designation to LMP01 for malignant glioma
The U.S. Food and Drug Administration has granted Orphan Drug Designation to LMP01 for the treatment of malignant glioma, which includes glioblastoma. The designation is given to investigational therapies for rare diseases affecting fewer than 200,000 people in the United States.
Orphan Drug Designation provides development incentives, including tax credits for qualified clinical testing and exemption from certain FDA user fees, as well as seven years of market exclusivity in the United States if the product is approved for the designated use.